{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=33", "query": { "condition": "Carcinoma of Head/Neck", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 1992, "total_pages": 200, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=34&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+Head%2FNeck&page=32&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T05:29:39.904Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05647122", "title": "First in Human Study of AZD9592 in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours", "Carcinoma Non-small Cell Lung", "Head and Neck Neoplasms", "Colorectal Neoplasms" ], "interventions": [ { "name": "AZD9592", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2022-12-21", "completion_date": "2028-08-03", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-19T05:29:39.904Z", "location_count": 15, "location_summary": "Duarte, California • North Haven, Connecticut • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "North Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05647122" }, { "nct_id": "NCT01221753", "title": "Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck", "Human Papilloma Virus" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "IMRT", "type": "RADIATION" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2011-07", "completion_date": "2017-07", "has_results": true, "last_update_posted_date": "2017-12-06", "last_synced_at": "2026-10-19T05:29:39.904Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01221753" }, { "nct_id": "NCT04670679", "title": "A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "ERAS-601", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Erasca, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 90, "start_date": "2020-12-15", "completion_date": "2026-06-01", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-19T05:29:39.904Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Sarasota, Florida • Boston, Massachusetts + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Henderson", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT04670679" }, { "nct_id": "NCT04453046", "title": "Hemopurifier Plus Pembrolizumab in Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Hemopurifier", "type": "DEVICE" }, { "name": "Pembrolizumab 200mg IV", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Aethlon Medical Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-10-22", "completion_date": "2022-11-14", "has_results": false, "last_update_posted_date": "2022-12-20", "last_synced_at": "2026-10-19T05:29:39.904Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04453046" }, { "nct_id": "NCT04521686", "title": "Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cholangiocarcinoma", "Chondrosarcoma", "Glioma", "Any Solid Tumor" ], "interventions": [ { "name": "LY3410738", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2020-10-01", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-19T05:29:39.904Z", "location_count": 17, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04521686" }, { "nct_id": "NCT00100789", "title": "S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "gemcitabine", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2005-01", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2012-10-01", "last_synced_at": "2026-10-19T05:29:39.904Z", "location_count": 123, "location_summary": "Anniston, Alabama • Mobile, Alabama • Aurora, Colorado + 81 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Montrose", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100789" }, { "nct_id": "NCT00448760", "title": "Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Floxuridine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Microarray analysis", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "Conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "GENETIC", "PROCEDURE" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 29, "start_date": "2004-10", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-10-19T05:29:39.904Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00448760" }, { "nct_id": "NCT06744296", "title": "Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Blood Draws and Tissue Sample(s)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massachusetts Eye and Ear Infirmary", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2025-02-03", "completion_date": "2029-01-06", "has_results": false, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-10-19T05:29:39.904Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06744296" }, { "nct_id": "NCT03646461", "title": "Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Ibrutinib 560mg PO daily (Imbruvica)", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2018-10-17", "completion_date": "2021-05-13", "has_results": true, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-19T05:29:39.904Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03646461" }, { "nct_id": "NCT04458909", "title": "Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Nasopharyngeal Carcinoma", "Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Metastatic Nasopharyngeal Nonkeratinizing Carcinoma", "Metastatic Nasopharyngeal Undifferentiated Carcinoma", "Nasopharyngeal Nonkeratinizing Carcinoma", "Recurrent Nasopharyngeal Carcinoma", "Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Recurrent Nasopharyngeal Undifferentiated Carcinoma", "Stage IV Nasopharyngeal Carcinoma AJCC v8", "Stage IVA Nasopharyngeal Carcinoma AJCC v8", "Stage IVB Nasopharyngeal Carcinoma AJCC v8" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2020-12-09", "completion_date": "2023-08-15", "has_results": true, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-19T05:29:39.904Z", "location_count": 322, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 204 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04458909" } ] }